Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013

Kimiko Ubukata, Naoko Chiba, Shigeo Hanada, Miyuki Morozumi, Takeaki Wajima, Michi Shouji, Satoshi Iwata

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

After 7-valent pneumococcal conjugate vaccine (PCV) for children was introduced in Japan in November 2010, we examined changes in Streptococcus pneumoniae serotypes and in genetic antimicrobial drug resistance of isolates from adults with invasive pneumococcal diseases. During April 2010–March 2013, a total of 715 isolates were collected from adults with invasive pneumococcal diseases. Seven-valent PCV serotypes in adults decreased from 43.3% to 23.8%, most noticeably for serotype 6B. Concomitantly, 23-valent pneumococcal polysaccharide vaccine (PPSV23) serotypes decreased from 82.2% to 72.2%; non-PPSV23 serotypes increased from 13.8% to 25.1%. Parallel with serotype changes, genotypic penicillin-resistant S. pneumoniae decreased from 32.4% to 21.1%, and 6 non-PPSV23 serotypes emerged (6D, 15A, 15C, 16F, 23A, and 35B). Respective vaccine coverage rates for 13-valent PCV and PPSV23 differed by disease: 73.9% and 84.3% for patients with pneumonia, 56.4% and 69.2% for patients with bacteremia and sepsis, and 45.7% and 69.3% for patients with meningitis.

Original languageEnglish
Pages (from-to)1956-1965
Number of pages10
JournalEmerging Infectious Diseases
Volume21
Issue number11
DOIs
Publication statusPublished - 2015 Nov 1

Fingerprint

Drug Resistance
Japan
Vaccination
Conjugate Vaccines
Pneumococcal Vaccines
Streptococcus pneumoniae
Microbial Drug Resistance
Bacteremia
Serogroup
Meningitis
Penicillins
Sepsis
Pneumonia
Vaccines

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Epidemiology

Cite this

Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013. / Ubukata, Kimiko; Chiba, Naoko; Hanada, Shigeo; Morozumi, Miyuki; Wajima, Takeaki; Shouji, Michi; Iwata, Satoshi.

In: Emerging Infectious Diseases, Vol. 21, No. 11, 01.11.2015, p. 1956-1965.

Research output: Contribution to journalArticle

Ubukata, Kimiko ; Chiba, Naoko ; Hanada, Shigeo ; Morozumi, Miyuki ; Wajima, Takeaki ; Shouji, Michi ; Iwata, Satoshi. / Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013. In: Emerging Infectious Diseases. 2015 ; Vol. 21, No. 11. pp. 1956-1965.
@article{704db42f92804214b2583239bee05544,
title = "Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013",
abstract = "After 7-valent pneumococcal conjugate vaccine (PCV) for children was introduced in Japan in November 2010, we examined changes in Streptococcus pneumoniae serotypes and in genetic antimicrobial drug resistance of isolates from adults with invasive pneumococcal diseases. During April 2010–March 2013, a total of 715 isolates were collected from adults with invasive pneumococcal diseases. Seven-valent PCV serotypes in adults decreased from 43.3{\%} to 23.8{\%}, most noticeably for serotype 6B. Concomitantly, 23-valent pneumococcal polysaccharide vaccine (PPSV23) serotypes decreased from 82.2{\%} to 72.2{\%}; non-PPSV23 serotypes increased from 13.8{\%} to 25.1{\%}. Parallel with serotype changes, genotypic penicillin-resistant S. pneumoniae decreased from 32.4{\%} to 21.1{\%}, and 6 non-PPSV23 serotypes emerged (6D, 15A, 15C, 16F, 23A, and 35B). Respective vaccine coverage rates for 13-valent PCV and PPSV23 differed by disease: 73.9{\%} and 84.3{\%} for patients with pneumonia, 56.4{\%} and 69.2{\%} for patients with bacteremia and sepsis, and 45.7{\%} and 69.3{\%} for patients with meningitis.",
author = "Kimiko Ubukata and Naoko Chiba and Shigeo Hanada and Miyuki Morozumi and Takeaki Wajima and Michi Shouji and Satoshi Iwata",
year = "2015",
month = "11",
day = "1",
doi = "10.3201/eid2111.142029",
language = "English",
volume = "21",
pages = "1956--1965",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "11",

}

TY - JOUR

T1 - Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013

AU - Ubukata, Kimiko

AU - Chiba, Naoko

AU - Hanada, Shigeo

AU - Morozumi, Miyuki

AU - Wajima, Takeaki

AU - Shouji, Michi

AU - Iwata, Satoshi

PY - 2015/11/1

Y1 - 2015/11/1

N2 - After 7-valent pneumococcal conjugate vaccine (PCV) for children was introduced in Japan in November 2010, we examined changes in Streptococcus pneumoniae serotypes and in genetic antimicrobial drug resistance of isolates from adults with invasive pneumococcal diseases. During April 2010–March 2013, a total of 715 isolates were collected from adults with invasive pneumococcal diseases. Seven-valent PCV serotypes in adults decreased from 43.3% to 23.8%, most noticeably for serotype 6B. Concomitantly, 23-valent pneumococcal polysaccharide vaccine (PPSV23) serotypes decreased from 82.2% to 72.2%; non-PPSV23 serotypes increased from 13.8% to 25.1%. Parallel with serotype changes, genotypic penicillin-resistant S. pneumoniae decreased from 32.4% to 21.1%, and 6 non-PPSV23 serotypes emerged (6D, 15A, 15C, 16F, 23A, and 35B). Respective vaccine coverage rates for 13-valent PCV and PPSV23 differed by disease: 73.9% and 84.3% for patients with pneumonia, 56.4% and 69.2% for patients with bacteremia and sepsis, and 45.7% and 69.3% for patients with meningitis.

AB - After 7-valent pneumococcal conjugate vaccine (PCV) for children was introduced in Japan in November 2010, we examined changes in Streptococcus pneumoniae serotypes and in genetic antimicrobial drug resistance of isolates from adults with invasive pneumococcal diseases. During April 2010–March 2013, a total of 715 isolates were collected from adults with invasive pneumococcal diseases. Seven-valent PCV serotypes in adults decreased from 43.3% to 23.8%, most noticeably for serotype 6B. Concomitantly, 23-valent pneumococcal polysaccharide vaccine (PPSV23) serotypes decreased from 82.2% to 72.2%; non-PPSV23 serotypes increased from 13.8% to 25.1%. Parallel with serotype changes, genotypic penicillin-resistant S. pneumoniae decreased from 32.4% to 21.1%, and 6 non-PPSV23 serotypes emerged (6D, 15A, 15C, 16F, 23A, and 35B). Respective vaccine coverage rates for 13-valent PCV and PPSV23 differed by disease: 73.9% and 84.3% for patients with pneumonia, 56.4% and 69.2% for patients with bacteremia and sepsis, and 45.7% and 69.3% for patients with meningitis.

UR - http://www.scopus.com/inward/record.url?scp=84944602937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944602937&partnerID=8YFLogxK

U2 - 10.3201/eid2111.142029

DO - 10.3201/eid2111.142029

M3 - Article

C2 - 26485679

AN - SCOPUS:84944602937

VL - 21

SP - 1956

EP - 1965

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 11

ER -